Thymic Stromal Lymphopoietin

TSLP, IL-33, and IL-4Rα form the hierarchical cytokine signaling cascade that initiates and sustains Type 2 (T2) mucosal inflammation across the "atopic march"—encompassing allergic and eosinophilic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), atopic dermatitis (AD), eosinophilic esophagitis (EoE), and subset phenotypes of chronic obstructive pulmonary disease (COPD). At the apex of this cascade sit three epithelial barrier "alarmins"—thymic stromal lymphopoietin (TSLP on chromosome 5q22.1), interleukin-33 (IL33 on Chr9p24.1), and interleukin-25 (IL25 / IL-17E on Chr14q11.2)—which are released immediately by respiratory, sinonasal, and epidermal epithelial cells upon exposure to viral double-stranded RNA (rhinovirus, RSV), cysteine proteases from house dust mites (Dermatophagoides pteronyssinus Der p 1) or fungi (Alternaria alternata), and airborne particulate pollutants.

Once released into the lamina propria, TSLP and IL-33 activate both innate Group 2 innate lymphoid cells (ILC2s) and adaptive OX40L⁺ dendritic-cell-primed Type 2 helper T (Th2) lymphocytes to secrete the three canonical Type 2 effector cytokines: interleukin-4 (IL-4), interleukin-13 (IL-13) (both signaling through the shared IL-4Rα subunit encoded by IL4R on Chr16p12.1), and interleukin-5 (IL-5, encoded on Chr5q31.1). Human population genetics—most notably the discovery of a rare loss-of-function splice variant in IL33 (rs146597587) that halves blood eosinophil counts and lowers asthma risk by ~40% to 50%—combined with targeted monoclonal antibodies (tezepelumab anti-TSLP, itepekimab/astegolimab/tozorakimab anti-IL-33/ST2, dupilumab anti-IL-4Rα, and mepolizumab/benralizumab anti-IL-5/IL-5Rα) has revolutionized precision respiratory and dermatologic medicine.

TSLP (Chr5q22.1): Long vs Short Isoforms and TSLPR–IL-7Rα–STAT5 Activation

Encoded by the TSLP gene on chromosome 5q22.1 (4 exons), thymic stromal lymphopoietin (TSLP) is a four-helix-bundle cytokine distantly related to IL-7. Human epithelial cells transcribe TSLP from two distinct promoters regulated by alternative splicing and NF-κB/AP-1 activation: a constitutively expressed short isoform (sfTSLP, 63 amino acids) that exerts homeostatic antimicrobial barrier effects, and an inducible long pro-inflammatory isoform (lfTSLP, 159 amino acids, ~15 kDa) whose expression surges 10- to 50-fold during viral or allergen challenge (further amplified by common non-coding GWAS risk alleles such as rs1837253 upstream of TSLP).

Secreted lfTSLP initiates signaling via a sequential electrostatic capture mechanism:

1. Binary Complex Formation (TSLP:TSLPR): Positively charged surface patches on TSLP first bind with nanomolar affinity (K_d ≈ 10–30 nM) to the negatively charged extracellular cytokine-binding homology region of the TSLP receptor (TSLPR, encoded by CRLF2 in the pseudoautosomal region ChrXp22.33/Yp11.32).
2. Ternary Recruitment of IL-7Rα and JAK1/JAK2–STAT5 Phosphorylation: The TSLP:TSLPR binary interface creates a composite binding site that recruits the interleukin-7 receptor α-chain (IL-7Rα / CD127) (ternary K_d ≈ 30–100 pM). Dimerization brings JAK2 (bound to TSLPR) and JAK1 (bound to IL-7Rα) into proximity to trans-phosphorylate STAT5A/STAT5B (and STAT3).

Uniquely among airway cytokines, TSLPR is expressed across both Type 2 (DCs, ILC2s, mast cells, basophils, eosinophils) and non-Type 2 (Th17 precursors, airway smooth muscle cells, sensory TRPA1⁺ neurons) compartments. On myeloid dendritic cells (mDCs), TSLP–STAT5 upregulates OX40L (TNFSF4) and CCL17 (TARC), licensing OX40⁺ naive CD4⁺ T cells to differentiate into IL-4/IL-5/IL-13-producing Th2 cells while simultaneously conferring corticosteroid resistance on airway ILC2s via STAT5/BCL-xL anti-apoptotic survival. This dual innate/adaptive breadth explains why the human IgG2λ monoclonal antibody tezepelumab (Tezspire)—which binds TSLP helices A and D to block TSLPR engagement—reduced annualized asthma exacerbations by 56% overall in the Phase 3 NAVIGATOR trial, including a 41% reduction in patients with low baseline blood eosinophils (<150 cells/μL) and low fractional exhaled nitric oxide (FeNO < 25 ppb) where downstream biologics fail.

IL-33 (Chr9p24.1): Chromatin Tethering, Protease Cleavage, and rs146597587 Protection

Encoded by IL33 on chromosome 9p24.1 (8 exons, 270 amino acids, ~30 kDa), interleukin-33 (IL-33) is an IL-1 family β-trefoil cytokine with an unconventional dual life. Unlike classical cytokines, IL-33 lacks an N-terminal endoplasmic-reticulum signal peptide; instead, its N-terminal domain (residues 1–65) contains a chromatin-binding motif (residues 40–58) that docks directly into the acidic patch of nucleosomal H2A–H2B histones, sequestering full-length IL-33 inside the nucleus of healthy resting epithelial and endothelial cells (so that apoptotic caspases-3/7 cleave Asp178 inside the β-trefoil fold to inactivate IL-33 during peaceful programmed cell death).

When epithelial cells undergo necrotic lytic injury or mechanical stretch, full-length IL-33(1–270) is spilled into the extracellular space, where exogenous allergen proteases (Der p 1, Alternaria serine proteases) and endogenous mast-cell chymase and neutrophil elastase/cathepsin G cleave its central protease-sensor domain (residues 90–111), liberating hyper-active mature IL-33(95–270) or IL-33(109–270) with 30- to 60-fold higher biological potency. Reduced mature IL-33 (IL-33^red, containing four free cysteines: Cys208, Cys227, Cys232, Cys259) binds its transmembrane receptor ST2L (encoded by IL1RL1 on Chr2q12.1) and recruits the IL-1 receptor accessory protein (IL-1RAcP), signaling via MyD88–IRAK1/IRAK4–TRAF6 to activate NF-κB and p38 MAPK in GATA3^hi ILC2s, mast cells, and eosinophils (whereas extracellular oxidation into disulfide-bonded IL-33^ox switches signaling to a RAGE–EGFR epithelial mucin hyperplasia pathway, blocked by tozorakimab).

Human genetics provided definitive proof of the IL-33–ST2 axis in asthma: in 2017, sequencing of over 200,000 individuals in Iceland and the UK Biobank identified a rare splice-acceptor mutation at the boundary of Intron 6 and Exon 7 of IL33 (rs146597587, c.487-1G>C, allele frequency ~0.45% in Europeans). This loss-of-function allele truncates the C-terminal β-trefoil domain (premature stop at residue 231), causing misfolding and abolishing ST2 binding. Heterozygous carriers exhibit a ~30% to 50% reduction in blood eosinophils and a 46% reduction in asthma risk (OR ≈ 0.54), while rare c.487-1G>C homozygotes are healthy and completely protected against asthma—directly motivating itepekimab (anti-IL-33), astegolimab (anti-ST2), and tozorakimab, which show strong efficacy in both asthma and former-smoker COPD (AERIFY trials).

Type I vs Type II IL-4Rα Complexes and Dupilumab Dual Blockade

Downstream of TSLP and IL-33, the signature pathology of Type 2 disease is executed by IL-4 and IL-13 (encoded 12.5 kb apart within the Chr5q31.1 cytokine cluster and governed by a shared RAD50 locus control region) signaling through two heterodimeric receptors sharing the IL-4Rα subunit (IL4R on Chr16p12.1):

1. Type I Receptor (IL-4Rα + common γ-chain γ_c / IL2RG): Expressed predominantly on hematopoietic cells (T cells, B cells). Engaged solely by IL-4, activating JAK1 and JAK3 to phosphorylate STAT6, which drives GATA3 Th2 polarization and triggers B-cell activation-induced cytidine deaminase (AID) immunoglobulin class-switching to IgE (ε-germline transcription).
2. Type II Receptor (IL-4Rα + IL-13Rα1): Expressed on non-hematopoietic structural cells (airway epithelial goblet cells, bronchial smooth muscle, fibroblasts, and epidermal keratinocytes) as well as myeloid cells. Engaged by both IL-4 and IL-13, activating JAK1 and TYK2/JAK2 to phosphorylate STAT6.

In bronchial epithelium, IL-13–STAT6 signaling directly transcribes inducible nitric oxide synthase (NOS2 / iNOS, the source of clinical fractional exhaled nitric oxide, FeNO), MUC5AC (the sticky pathological mucin that forms occlusive airway mucus plugs via pendrin/SLC26A4 and disulfide cross-linking), periostin (POSTN), and eotaxin-3 (CCL26), while downregulating epidermal filaggrin (FLG) and involucrin in atopic dermatitis. Early clinical trials of biologics blocking IL-4 alone (pascolizumab) or IL-13 alone (lebrikizumab/tralokinumab in asthma) failed to suppress both IgE switching and airway mucus/smooth-muscle remodeling simultaneously. By targeting the shared IL-4Rα subunit, the human IgG4 monoclonal antibody dupilumab (Dupixent) neutralizes both Type I (IL-4) and Type II (IL-4/IL-13) signaling, reducing severe exacerbations by 50% to 70% in eosinophilic/Type-2 asthma, CRSwNP, atopic dermatitis, eosinophilic esophagitis, and T2-high COPD (BOREAS and NOTUS trials).

IL-5–IL-5Rα Signaling and Afucosylated ADCC Depletion (Benralizumab)

Operating in parallel with IL-4/IL-13, interleukin-5 (IL-5) is a disulfide-linked homodimeric four-helix-bundle cytokine that binds the specific IL-5 receptor α-chain (IL-5Rα / IL5RA on Chr3p26.2) paired with the signaling common β-chain (β_c / CSF2RB) on bone-marrow eosinophil progenitors (EoPs), mature eosinophils, and basophils. IL-5–JAK2–STAT5 signaling is the obligatory survival and mobilization factor that drives eosinophil egress from bone marrow (synergizing with eotaxin-1/3 CCR3 chemotaxis) and inhibits eosinophil apoptosis in inflamed airways. Whereas mepolizumab (Nucala) and reslizumab bind soluble IL-5 ligand (lowering blood eosinophils by ~80%–85%), benralizumab (Fasenra) is a humanized IgG1κ antibody directed against domain 1 of membrane IL-5Rα whose Fc region is engineered in α-1,6-fucosyltransferase (FUT8)-knockout cells to be completely afucosylated. Removing core fucose increases binding affinity for FcγRIIIa (CD16a) on natural killer (NK) cells by ~50-fold, triggering rapid antibody-dependent cellular cytotoxicity (ADCC) that depletes blood and sputum eosinophils to 0 cells/μL within 24 hours without causing toxic eosinophil degranulation.

Why is tezepelumab effective in non-eosinophilic (Type 2-low) asthma where dupilumab and mepolizumab show limited benefit?

Dupilumab (anti-IL-4Rα) and mepolizumab/benralizumab (anti-IL-5/IL-5Rα) block downstream Type 2 effector pathways, so they require active eosinophilic or IL-13/FeNO-driven inflammation. In contrast, tezepelumab neutralizes the upstream epithelial alarmin TSLP, which acts not only on ILC2s and Th2 cells but also directly on airway smooth muscle cells, mast cells, sensory nerves, and Th17/neutrophilic dendritic-cell pathways, reducing exacerbations by 41% even in T2-low patients (eosinophils < 150/μL and FeNO < 25 ppb).

How does the rare IL33 splice variant rs146597587 protect against asthma, and why is IL-33 stored inside the cell nucleus?

Full-length IL-33 lacks a classical secretion signal and is tethered via its N-terminal chromatin-binding motif to histone H2A–H2B dimers inside the nucleus so that healthy cells do not constitutively activate ST2⁺ ILC2s and mast cells (and apoptotic caspases-3/7 cleave and inactivate IL-33 during normal cell turnover). Only necrotic epithelial damage releases IL-33. The rare rs146597587 (c.487-1G>C) splice variant truncates the C-terminal ST2-binding domain of IL-33, halving blood eosinophil counts and lowering asthma risk by 46%.

Why did blocking the shared IL-4Rα receptor subunit (dupilumab) succeed in asthma after antibodies against IL-4 alone or IL-13 alone fell short?

IL-4 and IL-13 have partially redundant and partially distinct roles in asthma: IL-4 signals through the Type I receptor (IL-4Rα + γ_c) on T and B cells to drive Th2 polarization and IgE synthesis, whereas IL-13 (and IL-4) signals through the Type II receptor (IL-4Rα + IL-13Rα1) on airway epithelium and smooth muscle to drive MUC5AC mucus plugging, iNOS (FeNO), and bronchial hyper-responsiveness. Blocking IL-4 alone leaves IL-13 mucus plugging untouched, while blocking IL-13 alone leaves IL-4-driven Th2/IgE amplification intact; targeting IL-4Rα with dupilumab shuts down both receptors simultaneously.

1. Menzies-Gow, A., Corren, J., Bourdin, A., et al. (2021). "Tezepelumab in adults and adolescents with severe, uncontrolled asthma." New England Journal of Medicine, 384(19), 1800–1809. https://doi.org/10.1056/NEJMoa2034975
2. Smith, D., Helgason, H., Sulem, P., et al. (2017). "A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma." PLOS Genetics, 13(3), e1006659. https://doi.org/10.1371/journal.pgen.1006659
3. Castro, M., Corren, J., Pavord, I. D., et al. (2018). "Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma." New England Journal of Medicine, 378(26), 2486–2496. https://doi.org/10.1056/NEJMoa1804092
4. Bhatt, S. P., Rabe, K. F., Hanania, N. A., et al. (2023). "Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation." New England Journal of Medicine, 389(3), 205–214. https://doi.org/10.1056/NEJMoa2303951